Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant encorafenib + binimetinib vs placebo in resected stage II BRAF-mutated melanoma
2021-000743-41Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in melanoma comparing Encorafenib + binimetinib with Placebo (2 arms). Primary endpoint: Recurrence-free survival. Started Oct 2021; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2021-000743-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000743-41.